



Biotech Daily

Friday January 1, 2021

Special Edition

2020: BDI-40 UP 24%; ASX200 DOWN 1.5%, BIG CAPS UP 6%, NBI UP 26%

Amplia Up 550%, Alterity 271%, Telix 170%, Immutep 166%, Cyclopharm 119%

The Biotech Daily Top-40 Index (BDI-40) climbed a further 1.7% in December to close the year up 23.7 percent to a record collective market capitalization of \$18,348 million.

Despite, or because of, the coronavirus, biotech had a very good year.

The benchmark S&P ASX200 fell 1.5 percent for the year to December 31, while the Nasdaq Biotechnology Index (NBI) was up 25.7 percent, and the three Big Caps of Cochlear, CSL and Resmed (which are not included in the BDI-40) climbed a further 6.0 percent for the year, although down 5.2 percent in December.

CSL was up 2.9 percent to close the year at \$128,840 million, Resmed rose 25.8 percent to \$39,622 million, with Cochlear down 4.4 percent to \$12,425 million.

Twenty-four of the BDI-40 stocks were up in 2020, with 12 up more than 100 percent and 20 up more than 50 percent; while 16 fell - with eight down by more than 20 percent.

While Amplia was the best of the BDI-40, up 550.0 percent to \$26 million, it was from a very low base of \$4 million.

More significantly, the other Dr Christian Behrenbruch-founded company, Telix, was the best of the BDI-20 up 169.7 percent for the year to December 31, to \$1,060 million (welcome to the Billion Dollar Club). Other big-hitters in the BDI-20 were Immutep (166.3%), Cyclopharm (118.5%), Polynovo (97.0%) and Genetic Signatures (95.2%).


Including Amplia, the Second 20 had nine companies up by more than 100 percent: Alterity (270.6%), Optiscan (250.0%), Imugene (243.5%), Kazia (239.5%), Proteomics (232%), Osprey (176.9%), Universal Biosensors (126.5%) and Patrys (104.8%).

Avita led the falls, down 61.2 percent to \$530 million, followed by Ellex (54.1%), Pharmaxis (41.3%), Neuren 40.7%), Compumedics (37.3%), Next Science (28.3%), Actinogen (25%), Clinuvel (21.6%), Medical Developments (19.2%) and Opthea (19.2%).


Cannabis Corner recovered 38.6 percent in 2020 to a collective market capitalization of \$1,660 million, but still 13.2 percent from its July 31, 2019 high of \$1,913 million.

On the Nasdaq, Queensland's Protagonist climbed 312.5% to \$1,126 million, Israel's Redhill with Australian assets was up 29.9 percent for the year to \$395 million but Eypoint (formerly Psivida) fell 45.8 percent to \$129 million.


BDI-40 v ASX200 Jun 30, 2006 to Dec 31, 2020- Adjusted



Big Caps \$m (Cochlear, CSL, Resmed) Dec 31, 2015 – Dec 31, 2020



BDI-40 (\$m) v S&P ASX 200 – Dec 31, 2019 – Dec 31, 2020 (current, raw data)



Biotech Daily Top 40 with Market Capitalization At December 31, 2020

Company \$Am	Jan-20	Dec-20	Jan-21
Cochlear	12,996	14,491	12,425
CSL	125,160	135,300	128,840
Resmed	31,485	40,953	39,622
BDI-20			
Avita	1,366	624	530
Clinuvel	1,406	1,000	1,103
Compumedics	142	92	89
Cyclopharm	92	193	201
Cynata	107	93	95
Ellex	111	51	51
Genetic Signatures	147	255	287
Immutep	101	166	269
Medical Developments	574	431	464
Mesoblast	1,116	2,440	1,322
Nanosonics	1,908	2,005	2,417
Neuren	248	139	147
Opthea	802	777	648
Paradigm	577	668	576
Pharmaxis	63	36	37
Polynovo	1,302	2,122	2,565
Pro Medicus	2,323	3,078	3,560
Starpharma	451	518	635
Telix	393	988	1,060
Volpara	399	347	360
Second 20			
Actinogen	40	32	30
Alterity	17	65	63
Amplia	4	25	26
Antisense	38	59	75
Dimerix	24	50	47
Impedimed	84	178	135
Imugene	138	539	474
Kazia	43	174	146
LBT Innovations	38	36	35
Next Science	339	240	243
Oncosil	107	143	98
Optiscan	18	63	63
Orthocell	90	78	83
Osprey	13	36	36
Patrys	21	31	43
Prescient	24	43	43
Proteomics	25	55	83
Resonance	96	71	107
Universal Biosensors	34	82	77
Uscom	18	26	25

* Biotech Daily editor, David Langsam, owns shares in Acrux, Alcidion, Alterity, Amplia, BTC Health, Clarity, Cochlear, Cynata, Nanosonics, Neuren, Patrys, Polynovo, Telix, Volpara and non-biotechnology stocks. Through Australian Ethical Superannuation he has an indirect interest in other biotechnology companies. These holdings are liable to change.

<https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/>

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
email: editor@biotechdaily.com.au; www.biotechdaily.com.au; twitter: @biotech_daily